Course:PHAR451/Syllabus

Course Syllabus

Course Coordinator: [mailto: janicem@mail.ubc.ca; Ms. Janice Moshenko,], B.Sc(Pharm), M.Sc.(Pharm), RPh, CEC

PHAR 451 Connect Site: Connect

Course Twitter feed: @pharm451

Course Feedback & Questions: Please use the Discussion Board(s) in Connect and/or email [1]

Office: UBC Pharmaceutical Sciences Building, Room 3513

Course Location: UBC PHRM 1101

Course Schedule: Timing variable based on the P4X1 course master schedule available on the course Connect site.

Credits: 2

Graduate Teaching Assistant: [mailto: atiqmzam@mail.ubc.ca; Mr. Mohammad Atiquzzaman]

Course Description

PHAR 451 focuses on the pharmacotherapeutics (i.e., the application of drug therapy in patients) of the major endocrine and cardiovascular diseases commonly encountered by pharmacists. The course is delivered in a coordinated fashion with PHAR 471 (Pathophysiology), PHAR 441 (Pharmacology), P430 (Biomolecular & Pharmaceutical Chemistry) and P461 (Patient self-care) such that the pathophysiological and pharmacological basis for the therapeutics is laid down before the applicable P451 session occurs. This is depicted in UBC Connect. [URL]

Instructional Goals and Student Performance Objectives

Relevant Ability-Based Outcomes for the UBC B.Sc.(Pharm.) Degree:

1. Critical thinking skills
2. Information access and evaluation skills
3. Apply and integrate knowledge
4. Meet patient’s drug-related needs

Course Goal

To equip students to successfully provide pharmacist care in an evidence-based practice paradigm to patients with the endocrine and cardiovascular diseases addressed in the course during their experiential clerkships.

Course Learning Objectives

By the end of each disease module, augmented by CAPS case work, students will be able to:

1. Given a patient’s diagnosis and history: identify the common signs and symptoms of the disorder, list the goals of therapy, list the viable treatment alternatives based on the best available evidence, recommend a rational approach to the therapy of the disorder and justify that approach;
2. List the most common potential adverse effects, drug interactions and other drug-related complications of the therapy;
3. Identify and describe the important patient education points for the planned treatment regimen;
4. Describe the expected outcome(s) of therapy and the appropriate therapeutic monitoring parameters to ensure achievement of outcomes;
5. Identify potential or actual drug-related problems and explain how they can be prevented or managed.

Content Selection and Organization

Current pharmacotherapeutics for the following diseases are addressed in this course:

Endocrine module: diabetes, hyperthyroidism, hypothyroidism, endometriosis, menopause, osteoporosis, hormonal contraception, abortion.

Cardiovascular module: hypertension, CV risk estimation, hyperlipidemia, chronic angina, acute coronary syndromes, venous thrombosis, heart failure, stroke prevention, atrial fibrillation, anemia, erectile dysfunction.

Instructional Activities

All sessions are case-based: one or more patient cases will form the context for the session. Instructors will employ appropriate techniques to foster active learning by students. This may include pre-session preparation for in-class discussion of cases or evidence, in-class small group discussion of approaches to patient cases, technology-enabled real-time surveys in class, post-session assignments, and other strategies as appropriate.

Most sessions are captured for later online review by students.

Assessment Methods & Grading Practices and Policies

Connection Between Course Learning Objectives and Assessment / Grading Practices

Examinations will consist of patient case scenarios in which students will be required to exhibit the abilities described in the Course Objectives. This will involve multiple-choice questions, short-answer questions, and multi-sentence explanations.

Students will be assessed based on performance in the Diabetes/CV module and a final exam. The final exam will represent 75% of the total course grade and will cover all course material not covered in the Diabetes/CV module.

Students are expected to adhere to UBC’s Rules Governing Formal Examinations

Students are expected to adhere to UBC’s Academic Misconduct policies.

Supplemental FINAL examinations of the entire course material are allowed in this course, provided all of UBC Faculty of Pharmaceutical Sciences’ criteria for Supplemental Exams are met. Per Faculty policy, a supplemental exam will form 100% of the course mark.

Texts & Other Resources

• Pre-reading assigned by the session instructor will be posted in UBC Connect. Students are responsible for determining the pre-session assignments/readings.
• Since the course is firmly rooted in evidence-based practice, a comprehensive resource for students to deepen their knowledge and/or use as a reference is provided at: www.vhpharmsci.com/decisionmaking

Disclaimer: this syllabus is tentative, and subject to change according to the needs and interests of the class.